API Ibrutinib Raw Material Powder Ibrutinib Pharmaceutical Intermediate Ibrutinib

• Customization: Available
• Powder: Yes
• Customized: Customized
• Model NO.: Dsung-Ibrutinib
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: Powder
• Purity: >99%
• Product Name: Ibrutinib
• Appearance: White to off-White Powder
• Grade: Pharmaceutical Grade
• Assay: HPLC 99%
• Application: Pharmaceutical Intermediate
• Specific: COA
• Test Method: HPLC
• Shelf Life: 2 Years
• CAS No.: 936563-96-1
• Mf: C25h24n6o2
• MW: 440.507
• Density: 1.34
• Melting Point: 149-158 C
• Boiling Point: 715.0+-60.0 C(Predicted)
• Refractive Index: 1.69
• Transport Package: Negotiable
• Specification: 99%
• Trademark: D-Sung
• Origin: Shaanxi
• Production Capacity: 500 Kg/Month

Product Description

API Ibrutinib Raw Material Powder Ibrutinib Pharmaceutical Intermediate Ibrutinib

 

Product Description

Product Details

Product Name	Ibrutinib
Appearance	White to off-white powder
CAS No.	936563-96-1
MF	C25H24N6O2
MW	440.507

Ibrutinib is a white or white solid, soluble in dimethyl sulfoxide, soluble in methanol, insoluble in water;  It is a small molecule BTK inhibitor that can covalently bind to cysteine residues in the active center of BTK, thereby inhibiting its activity. According to lu for his can inhibit malignant B lymphocyte proliferation and survival in the body.

Application & Function

Ibrutinib is a Bruton's tyrosine kinase (BTK) inhibitor used to treat chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL).    Both MCL and CLL are B-cell non-Hodgkin's lymphomas, which are refractory and easy to relapse.    Commonly used chemotherapy and immunotherapy are not targeted, and grade 3 or 4 adverse reactions often occur.    Ibrutinib can be targeted to bind with BTK necessary for the formation, differentiation, information transmission and survival of B lymphocytes, irreversibly inhibit the activity of BTK, and effectively inhibit the proliferation and survival of tumor cells;    and it is absorbed rapidly after oral administration, 1~ The maximum blood drug concentration reached 2 hours, and the adverse reaction is classified as 1 or 2, which will become a new choice for the treatment of CLL and MCL.

Specification